Patent ID: 8853237

Claim:
A compound having a structure represented by a formula: wherein each - - - - - is independently an optional covalent bond, wherein valence is satisfied; wherein Y 1 is C—R 3a ; wherein Y 2 is N; wherein one of Z 1 and Z 2 is C-L-Ar 1 , and the other is C—R 3b ; wherein L is —O—C(R 1a R 1b )— or —C(R 1a R 1b )—O—; wherein Ar 1 is phenyl with 0-3 substituents selected from halogen, cyano, C1-C4 alkyl, and C1-C4 alkyloxy, or Ar 1 is monocyclic heteroaryl having 0-3 substituents selected from halogen, cyano, C1-C4 alkyl, and C1-C4 alkyloxy; wherein each of R 1a and R 1b is independently selected from hydrogen and C1-C4 alkyl; wherein R 2 is selected from hydrogen; C1-C6 alkyl; (C1-C6 alkyloxy) C1-C6 alkyl; C3-C8 cycloalkyl; (C3-C8 cycloalkyl) C1-C6 alkyl; C2-C5 heterocyclyl; phenyl with 0-3 substituents selected from halogen, cyano, C1-C4 alkyl, and C1-C4 alkyloxy; (C1-C2 alkyl)phenyl with 0-3 substituents selected from halogen, cyano, C1-C4 alkyl, and C1-C4 alkyloxy; and monocyclic heteroaryl having 0-3 substituents selected from halogen, cyano, C1-C4 alkyl, and C1-C4 alkyloxy; wherein R 3a is selected from hydrogen, halogen, cyano, and C1-C4 alkyl; wherein R 3b is selected from hydrogen, halogen, cyano, and C1-C4 alkyl, or R 3a and R 3b are substituted on adjacent carbons and are covalently bonded and, together with the intermediate carbons, comprise an optionally substituted fused ring selected from 4- to 7-membered cycloalkenyl, 5- to 7-membered heteroaryl, and 6-membered aryl; wherein R 4a is selected from hydrogen and C1-C4 alkyl; wherein R 4b , when present, is selected from hydrogen and C1-C4 alkyl, or R 4a and R 4b are covalently bonded and, together with the intermediate carbon, comprise an optionally substituted 3- to 7-membered spirocycloalkyl; wherein R 5a is selected from hydrogen and C1-C4 alkyl; and wherein R 5b , when present, is selected from hydrogen and C1-C4 alkyl, or R 5a and R 5b are covalently bonded and, together with the intermediate carbon, comprise an optionally substituted 3- to 7-membered spirocycloalkyl; or a pharmaceutically acceptable salt thereof, wherein the compound exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.